Abstract: The present invention relates to new protein compositions, methods for producing said protein compositions, pharmaceutical compositions comprising said protein compositions and methods for treating infections caused by Neospora caninum. In particular, the present invention relates to a protein composition comprising the proteins specified in Table A in an amount of at least about 2 times (fold change) higher than the same protein present in the whole tachyzoite, as calculated by quantitative label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Abstract: The present invention relates to new protein compositions, methods for producing said protein compositions, pharmaceutical compositions comprising said protein compositions and methods for treating infections caused by Neospora caninum. In particular, the present invention relates to a protein composition comprising the proteins specified in Table A in an amount of at least about 2 times (fold change) higher than the same protein present in the whole tachyzoite, as calculated by quantitative label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Abstract: The present invention relates to a new isolate of Neospora caninum and to the extracts which may be produced therefrom. Said isolate presents a high degree of attenuation, which makes it suitable for the development of vaccines against neosporosis, and of diagnostic tests to detect infection by Neospora caninum in animals. It also describes pharmaceutical compositions wherein said isolate or extracts thereof are used for the prevention and treatment of the infections caused by Neospora caninum in animals.

Abstract: The present invention relates to the use of a new isolate of Neospora caninum for the development of diagnostic tests and for the manufacture of products for the treatment and prevention of the infection caused by Neospora. The use of a new isolate of Neospora caninum (filed in the Culture Collection of Algae and Protozoa, with access number CCAP 2051/1), and the extracts obtained therefrom, in the preparation of diagnostic tests and in the manufacture of products for the treatment and prevention of the infection caused by Neospora, is based on the ease with which the new isolate converts from the tachyzoite to the bradyzoite stage under in vitro conditions. Additionally and with the same applications, the polypeptides and the polynucleotides obtained from the new isolate and the immunoreactive antibodies developed against Neospora antigens are used.